Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0CNJHC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
JK06
|
|||||
| Synonyms |
JK06; SAL006
Click to Show/Hide
|
|||||
| Organization |
Salubris Pharmaceuticals (Originator)
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-5T4 antibody
|
Antibody Info | ||||
| Antigen Name |
Trophoblast glycoprotein (TPBG)
|
Antigen Info | ||||
| Payload Name |
MMAE
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
vedotin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key eligibility: Adults (≥18) with advanced/metastatic solid tumors (ECOG ≤1, measurable disease per RECIST 1.1). Major exclusions: active/unstable CNS metastases, recent major surgery (6 weeks), cardiovascular events (6 months), grade ≥2 neuropathy, live vaccinations (4 weeks), or hypersensitivity to JK06 components. Requires archival tumor samples and acceptable organ function (ANC ≥1,500/uL, platelets ≥100,000, bilirubin ≤1.5×ULN).
Click to Show/Hide
|
||||
| Administration Dosage |
Escalating repeated doses of JK06 administered intravenously. A cycle of treatment is defined as 21 days.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06667960 | Clinical Status | PHASE1|||PHASE2 | ||
| Clinical Description | A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK06, a 5T4 Antibody Drug Conjugate, in Patients with Unresectable Locally Advanced or Metastatic Cancer | ||||
| Primary Endpoint |
Primary objectives assess safety through DLT incidence (first 21 days), MTD/RP2D determination (up to 14 months), and treatment-emergent AE/SAE monitoring (treatment period through 28 days post-last dose) in advanced solid tumor patients receiving JK06.
|
||||
| Other Endpoint |
Secondary endpoints evaluate PK parameters (Cmax, AUC), immunogenicity (ADA levels), and efficacy measures (ORR/DCR by RECIST v1.1, PFS) through 104 weeks of treatment follow-up.
|
||||